Instrument Inactif

Autres langues Hansa Biopharma AB Nasdaq Stockholm

Actions

SE0002148817

Temps réel estimé Cboe Europe Autres places de cotation 14:58:25 29/04/2024			Varia. 5j.	Varia. 1 janv.
28,56 ^SEK	-82,51 %		-5,78 %	-38,73 %

18/04	Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024
18/04	Hansa Biopharma AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Hansa Biopharma Q1 - Improved European launch support	19/04
Hansa Biopharma interim report January-March 2024	18/04
Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	18/04
Hansa Biopharma Approves SEK372 Million Directed Share Issue	12/04
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12/04
Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024	02/04
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02/04
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21/03
Hansa Biopharma Hires New CFO	22/02
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02
Hansa Biopharma AB Announces CFO Changes	22/02
Hansa Biopharma - Improved sales prospects	05/02
Hansa Biopharma Year-end report January-December 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02/02
Hansa Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02/02
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	06/01
Hansa Biopharma and Newbridge Pharmaceuticals Forms Partnership to Enable Supply of Novel Treatment Idefirix to Kidney Transplant Patients in the Middle East and North Africa	06/01
Hansa Biopharma AB Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	06/01
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	15/12
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	14/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Hansa Biopharma AB Nasdaq Stockholm

Actions

SE0002148817

Autres langues

Filtres